Media coverage about Kadmon (NYSE:KDMN) has been trending somewhat positive on Thursday, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Kadmon earned a coverage optimism score of 0.21 on Accern’s scale. Accern also gave press coverage about the company an impact score of 46.2317429956025 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the news stories that may have effected Accern’s rankings:
- Kadmon (KDMN) & The Competition Head to Head Review (americanbankingnews.com)
- Kadmon (KDMN) versus Its Peers Critical Comparison (americanbankingnews.com)
- Head-To-Head Survey: Kadmon (KDMN) & Its Rivals (americanbankingnews.com)
- Kadmon (KDMN) Announces Updated Positive Phase 2 Data on KD025 in cGVHD – StreetInsider.com (streetinsider.com)
- Zacks: Analysts Expect Kadmon Holdings, Inc. (KDMN) Will Post Quarterly Sales of $4.07 Million (americanbankingnews.com)
Kadmon (NYSE:KDMN) opened at $3.64 on Thursday. Kadmon has a 1-year low of $2.05 and a 1-year high of $5.93.
Kadmon (NYSE:KDMN) last released its quarterly earnings results on Thursday, November 9th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.04). The firm had revenue of $2.28 million for the quarter, compared to analysts’ expectations of $5.69 million. The business’s revenue for the quarter was down 60.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($4.24) earnings per share. equities research analysts predict that Kadmon will post -1.61 earnings per share for the current fiscal year.
KDMN has been the topic of a number of analyst reports. Zacks Investment Research raised shares of Kadmon from a “sell” rating to a “hold” rating in a report on Tuesday, November 21st. WBB Securities cut shares of Kadmon from a “hold” rating to a “sell” rating and set a $3.00 target price on the stock. in a report on Monday, October 9th. Finally, HC Wainwright reissued a “buy” rating and set a $25.00 target price on shares of Kadmon in a report on Friday, November 17th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the stock. Kadmon currently has an average rating of “Hold” and an average price target of $9.75.
WARNING: This story was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://ledgergazette.com/2017/12/14/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-kadmon-kdmn-stock-price.html.
Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.